Published in J Clin Oncol on May 17, 2010
The proposed rule for U.S. clinical trial registration and results submission. N Engl J Med (2014) 1.51
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer (2014) 1.22
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. Clin Cancer Res (2015) 1.19
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials. Clin Cancer Res (2015) 1.07
Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol (2012) 1.01
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clin Cancer Res (2012) 0.94
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol (2012) 0.87
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol (2012) 0.83
Life-threatening dermatologic adverse events in oncology. Anticancer Drugs (2014) 0.78
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Nonspecific medication side effects and the nocebo phenomenon. JAMA (2002) 5.79
The reliability of medical record review for estimating adverse event rates. Ann Intern Med (2002) 4.02
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol (2001) 3.21
Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol (2005) 2.28
Factors affecting workload of cancer clinical trials: results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2002) 1.90
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer (2007) 1.36
Influence of physicians' attitudes on reporting adverse drug events: a case-control study. Med Care (1999) 1.24
The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies. Clin Pharmacol Ther (1993) 1.13
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med (2004) 19.45
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA (2011) 16.68
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA (2002) 6.21
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91
The genome of woodland strawberry (Fragaria vesca). Nat Genet (2010) 5.86
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2005) 5.31
Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg (2007) 5.30
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol (2008) 5.10
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature (2008) 4.87
Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum (2005) 4.63
Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol (2007) 4.60
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol (2011) 4.56
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
CT screening for lung cancer: five-year prospective experience. Radiology (2005) 4.33
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol (2012) 4.27
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol (2009) 4.09
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol (2005) 3.88
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol (2006) 3.83
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res (2006) 3.83
MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med (2007) 3.79
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol (2006) 3.70
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2005) 3.50
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling. Biometrics (2011) 3.38
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (2002) 3.34
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol (2013) 3.24
Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol (2003) 3.18
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res (2006) 3.15
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol (2009) 3.08
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation (2003) 2.99
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA (2007) 2.84
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol (2008) 2.74
The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum (2005) 2.74
Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74
Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med (2003) 2.68
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol (2012) 2.65
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol (2013) 2.61
Malignant primary cardiac tumors: review of a single institution experience. Cancer (2008) 2.59
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol (2008) 2.58
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med (2013) 2.54
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol (2009) 2.54
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg (2007) 2.52
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol (2009) 2.47
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol (2014) 2.42